- Main navigation
- CLIC & The CTSA Program
- News & Events
- Groups
- Common Metrics Initiative
- Education & Career Development
- Team Science & Collaboration
- Resources
- CTSA Program Projects & Initiatives
- Contact
- Search
Postdoctoral Fellowships 2023 Position Description The National Cancer Institute-funded Cancer Control Fellowship at the UTHealth School of Public Health is a quality program with an established, 29 year track record for postdoctoral fellows with an academic interest in cancer prevention and control. Join a thriving interdisciplinary research environment with research and engagement opportunities
Background: The gap between the development of evidence-based interventions (EBI) and their implementation in practice stalls translational science progress. Multiple factors, including mismatch of an identified need to an evidence-based response, low EBI awareness, and lack of technical support, slow the adoption of EBIs. Solutions in Action (SA) Workshops offer an interactive process designed to
The newly established UTHealth Institute for Implementation Science seeks a candidate who demonstrates interest and expertise in interdisciplinary implementation science. Under the supervision and mentorship of UTHealth Institute for Implementation Directors Bijal Balasubramanian, M.B.B.S, PhD & Maria E. Fernandez, PhD, the Postdoctoral Research Fellow will participate in, design, organize and
Clinical and research data are increasingly collected and aggregated in clinical data warehouses (CDWs). Access to these data is subject to local, state and national regulations. For multiple reasons, institutions differ in how they interpret and apply these regulations. Sometimes, inter-institutional differences are unavoidable, such as when regulations clearly require specific practices. However
There has been a true revolution in cancer treatment. Numerous genetic alterations are being targeted using new therapies with the potential for improved, less toxic – often durable - outcomes in advanced cancer. Response rates are 3-5% for unmatched treatment with new tyrosine kinases and other similar agents whereas a “high value” alteration can result in response rates of 30-50% for actionable
With its Lowering the Barriers program, the Texas CTSA Consortium is facilitating collaboration among the Texas CTSAs and other interested biomedical research institutions by an IRB reciprocity agreement and sharing of resources, expertise, and patient populations. The Texas CTSAs' BERD, bioinformatics, ethics, and PCIR components are meeting regularly to exchange best practices and tackle joint
Learning healthcare (LHC) incorporates learning seamlessly into everyday patient care and is crucial to rapidly advancing patient outcomes and ultimately population health. Observational studies are valuable in generating new hypotheses and identifying highly effective therapies (resulting in a published relative risk for adverse outcome <0.10 compared to placebo or usual care). However, the great